Status:
COMPLETED
Novel in Vivo Synaptic Imaging in Experienced Meditators
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Behavior, Health
Eligibility:
All Genders
28-70 years
Phase:
PHASE1
Brief Summary
To utilize positron emission tomography (PET) imaging to characterize the distribution of (aka \[11C\]APP311at the Yale PET Center) in cortical and subcortical areas in experienced meditators compared...
Detailed Description
The investigators will conduct a PET study of the novel SV2A imaging tracer \[11C\]UCB-J in participants, to characterize the distribution of \[11C\]UCB-J in cortical and subcortical areas in experien...
Eligibility Criteria
Inclusion
- Age 28-70 years
- Voluntary, written, informed consent
- Physically healthy by medical history, physical, ECG and laboratory examinations
- At least 10 years and 5,000 hours of regular meditation practice
- For females, non-lactating, no longer of child-bearing potential or agree to practice effective contraception during the study, as well as a negative serum pregnancy (β-HCG) test at screening, and negative urine pregnancy on PET scanning days.
Exclusion
- A history of significant psychiatric, medical (e.g., cardiovascular, renal) or neurological (e.g., cerebrovascular, seizure, traumatic brain injury) illness that is unstable and/or might affect the study objectives.
- Current or history of substance dependence (e.g., alcohol, nicotine, opiates, sedative hypnotics, etc.)
- Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year.
- Subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research PET scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
- Medical contraindications to participation in a magnetic resonance imaging procedure (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.)
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).
- Medications that effect SV2A binding (e.g., levetiracetam).
Key Trial Info
Start Date :
April 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05418608
Start Date
April 21 2022
End Date
April 1 2024
Last Update
July 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University PET Center
New Haven, Connecticut, United States, 06519